Product Images Fulvestrant
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 19 images provide visual information about the product associated with Fulvestrant NDC 68001-522 by Bluepoint Laboratories, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Fulvestrant Injection BPL Carton (Pharmez Site) Rev 06 22
 Rev 06-22.jpg "Fulvestrant Injection BPL Carton (Pharmez Site) Rev 06-22.jpg")
This is a description of Flivestrant Injection, a medicine to be administered through intramuscular injection. It is a solution containing 500 mg of Fulvestrant in 5 mL. The solution comes in two prefilled syringes with each containing 250 mg/mL (50 mg/imL) of the medicine. It is indicated only for single-dose use, and two syringes are included in each carton. The medicine must be stored in the refrigerator and protected from light. The text also notes that the solution is for intramuscular use only and contains two safety needles.*
Fulvestrant Injection BPL Label (Pharmez Site) Rev 06 22
 Rev 06-22.jpg "Fulvestrant Injection BPL Label (Pharmez Site) Rev 06-22.jpg")
carton - fulvestrant injection carton
This is a description for Fulvestrant Injection, a medication administered via intramuscular injection for breast cancer treatment. Each carton contains two single-dose prefilled syringes, each containing 250mg/5ml of Fulvestrant. The medication requires refrigeration between 2°C to 8°C and protection from light. The syringe should be used with SafetyGlide" shielding intramuscular injection needles. The carton includes instructions for the administration of the medication, and it is available only by prescription.*
chemical structure Fulvestrant - fulvestrant injection chemical structure
Figure 1 - fulvestrant injection figure 1
figure_10 - fulvestrant injection figure 10
Figure 11 - fulvestrant injection figure 11
This appears to be a graph displaying the Progression-Free Survival Probability of two groups of individuals receiving different treatments, Fulvestrant plus Abemaciclib and Fulvestrant Plus Placebo, over a 30-month period. The number of censored observations is also provided.*
Figure 12 - fulvestrant injection figure 12
Figure 13 - fulvestrant injection figure 13
Figure 14 - fulvestrant injection figure 14
Figure 2 - fulvestrant injection figure 2
Figure 3 - fulvestrant injection figure 3
Figure 4 - fulvestrant injection figure 4
Figure 5 - fulvestrant injection figure 5
fig 6 kaplan-maier PFS: Study 1 ITT Population - fulvestrant injection figure 6
This appears to be survival data for two different treatments of fulvestrant administered at different doses. The participants were followed up for a period of 45 months, and the number of participants at risk at different time points is given for each treatment group. The efficacy of the two doses can be compared by comparing the numbers at risk over time.*
Figure 7 Kaplan-Meier OS (Minimum Follow-up Duration of 50 Months): CONFIRM ITT Population - fulvestrant injection figure 7
The text is related to a graph showing the proportion of patients alive based on two different types of fulvestrant and the duration of time in months. It also includes the number of patients at risk for each type of fulvestrant at different months. There is a note about the tick marks indicating censored observations, and the statement that there were no statistically significant adjustments made for multiplicity. However, there is some garbled text, making it difficult to interpret the exact values in some cases.*
Figure_8.jpg - fulvestrant injection figure 8
figure_9 - fulvestrant injection figure 9
label - fulvestrant injection label
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.